Jiabao Renhe and Illumina reached a strategic cooperation by gene sequencing assisted reproduction
According to the data, the average incidence of infertility in China is 12.5%-15%. The IVF is the most effective solution for infertility patients. In 2015, the reproductive centers in mainland China completed more than 400,000 cycles. As technology continues to advance, the number of IVF cycles will increase by 20% per year. At the same time, in 2016, the national “two-child†policy was released. As the average childbearing age increased significantly, assisted reproduction became a hot topic.
It is reported that Beijing Jiabao Renhe Medical Technology Co., Ltd. and the US Illumina company recently held a signing ceremony in Beijing. The two sides have jointly developed and promoted strategic cooperation on diagnostic methods and solutions based on next-generation sequencing technologies in the field of assisted reproduction. The signing of this collaboration further indicates that genomics technology will play an increasingly important role in the field of assisted reproduction. Also participating in the signing ceremony were Jiabao Renhe Investment Fangjifeng Capital and Morningside Venture Capital.
Focus on assisted reproduction to create a more perfect clinical solution
Headquartered in Beijing, Jiabao Renhe has been focusing on assisted reproductive and genetic fields since its inception in 2011. It is a pioneer and leader in providing integrated next-generation sequencing solutions for assisted reproduction and genetics, and is the only one in the field. Platform solutions company.
At present, Garbo Renhe's PGS/PGD detection technology, sequencing platform and analysis system have covered more than 70% of the reproductive medicine centers approved by the state for PGD in mainland China. At the same time, based on the next-generation sequencing technology, Garbo Renhe also provides solutions for AZF deletion detection, male oligo-sperm gene detection, female ovarian premature aging gene detection and single-gene disease carrier screening.
The cooperation between Garbo Renhe and Illumina will focus on MiSeq/MiSeqDx, the world's first and only next-generation sequencing platform to receive FDA and European CE certification, and apply related reagents of GGS/PGD developed by Garbo Renhe. And analysis software to create a more suitable, more accurate and more efficient clinical testing platform and clinical solutions.
As a core component of the third generation of IVF technology, preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) technology have been receiving much attention. In recent years, next-generation sequencing technology for the medical field The technological revolution is continually infiltrating into various clinical departments. This time, Jiabao Ren, who has the highest market share in the domestic PGS/PGD market, and Illumina, the leader of global genomics technology, have joined forces to promote the development of the entire assisted reproductive technology and benefit more infertile patients. .
Selected raw materials, deep roasting and frying, give the coffee a balanced taste
Mellow milk fragrance, long finish, showing delicate baking aroma
3 In 1 Coffee Powder,3 In 1 Classic Coffee,Coffee 3 In 1 Powder,Freeze Dried Ground Coffee
KARAK , https://www.jskarak.com